Biodexa Pharmaceuticals Secures Flexible $35 Million Funding Agreement

Biodexa Pharmaceuticals ( (BDRX) ) has issued an announcement.

On January 17, 2025, Biodexa Pharmaceuticals entered into a securities purchase agreement with C/M Capital Master Fund, LP, to potentially sell up to $35 million in American Depositary Shares. This strategic agreement is designed to provide flexible funding options over a 36-month period, contingent on market conditions and trading prices, thereby potentially strengthening Biodexa’s financial position and operational capabilities.

More about Biodexa Pharmaceuticals

Biodexa Pharmaceuticals is a company focused on the pharmaceutical industry, engaged in the development and sale of medical products. The company is based in Cardiff, United Kingdom, and its market focus includes the issuance and trading of American Depositary Shares.

YTD Price Performance: 6.11%

Average Trading Volume: 151,665

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $2.52M

For a thorough assessment of BDRX stock, go to TipRanks’ Stock Analysis page.